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Abstract: This was a prospective cross-sectional study in which 126 female students between the 
ages of 18 and 30 years were evaluated for the frequency of polycystic ovary syndrome (PCOS) 
through clinical interview, questionnaire, and anthropometric measurements. The diagnostic 
criteria of the US National Institutes of Health criteria were used. Menstrual irregularities (MI) 
were identified, and clinical hyperandrogenism was evaluated by self-assessment of hirsutism 
using modified Ferriman–Gallwey score. Blood analysis was done for measurement of prolac-
tin, thyroid-stimulating hormone, and the androgen hormones. Of all the students, 37 (30.8%) 
had MI, 38 (31.7%) had clinical hirsutism, 37 (30.8%) had acne, and 76 (63.3%) had a family 
history of type 2 diabetes. The estimated frequency of PCOS was 18.33% according to the US 
National Institutes of Health definition. Hormonal analysis demonstrated a significant increase 
in androgens (total testosterone, dehydroepiandrosterone sulfate, and free testosterone), and a 
significant decrease in sex hormone-binding globulin in our PCOS group, with a P-value ,0.05. 
This study revealed a higher level of the androgen hormones among PCOS subjects with a 
frequency of PCOS (18.33%) similar to the global estimates of 10%–20%.
Keywords: polycystic ovary syndrome, PCOS, hyperandrogenism, HA, hirsutism, menstrual 
irregularities, MI, frequency, hormonal profile, phenotype, Qatar, biochemical profile
Introduction
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder worldwide 
that affects 6%–8% of women.1 Enlarged ovaries, chronic anovulation, irregular 
menstrual cycles, androgen excess, and insulin resistance with consequences of acne, 
hirsutism, and infertility problems are main characters of PCOS.2 Studies in PCOS 
show that there is considerable heterogeneity in PCOS females, and hence, the need 
for a set of criterion to diagnose PCOS emerged.3,4 Several criteria are currently used 
for the diagnosis and definition of PCOS, such as the US National Institutes of Health 
(NIH) criteria,5 the Rotterdam criteria,6 and the Androgen Excess Society criteria.7
There are currently no comparable data about the phenotype profile, frequency 
of PCOS, and its features among young women in Qatar. Furthermore, awareness 
of PCOS prevalence has increased recently with the realization that this syndrome 
involves far more than the reproductive system and has medical consequences on 
metabolic aspects (such as metabolic syndrome, obesity, dyslipidemia, and insulin 
resistance), endocrine disorders (such as diabetes), and cardiovascular diseases 
(such as hypertension and atherosclerosis). In addition, it affects the psychosomatic 
perspective in females with PCOS, by causing obstetric and gynecological problems, 
such as infertility and endometrial cancers. Infertility problems have an influence 
on the social life of a human being, especially females. The aim of this study was 
to determine the frequency of PCOS defined by the NIH criteria, and its features 
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among the female students at Qatar University (QU). Our 
ultimate goal is to increase the awareness of PCOS and to 
promote effective early medical intervention and healthy 
lives for women.
Subjects and methods
study subjects
A population of 126 female students were recruited for the 
study as representative of the young females of Qatar. The 
total number of students approached was 130, but after 
explanation, only 126 students decided to participate in the 
study. The participants were an unselected group of stu-
dents, and all females were invited to take part in the study, 
regardless of having any symptoms of PCOS. Six subjects 
were excluded due to insufficient blood samples, incomplete 
surveys, and use of devices for hair removal. The final study 
sample consisted of 120 eligible participants, and only one 
of them was married and had infertility problems, while the 
remaining were single. Therefore, a cross-sectional study 
was performed on the 120 random adult female QU students. 
A campaign called “PCOS study in Qatar University” was 
initiated that aimed at screening the female population 
for hormonal irregularities and those who exhibited any 
symptoms suggestive of PCOS. Personal communication, 
flyers, posters, and social media (Facebook and Twitter) 
were used to recruit the study subjects. The study subjects 
were recruited from April 2011 until December 2011. The 
age group of the participants was between 18 and 30 years, 
at least 2–3 years after menarche to avoid any irregularity 
in the menstrual cycle. The participants were interviewed 
by the principal investigators and thereafter were exam-
ined in the university clinic by the medical team to check 
their medical condition. The study was approved by QU’s 
Institutional Review Board (IRB) (QU-IRB; 58-E/11). All 
participants signed the written consent form after explana-
tion of the study, and they received a copy of the ethical 
approval document.
Definitions
PCOS was diagnosed based on the NIH criteria5 which define 
a PCOS case as having the following:
Oligomenorrhea or amenorrhea, and clinical and/or bio-
chemical evidence of hyperandrogenism with the exclu-
sion of other conditions that can be involved in menstrual 
irregularities and hirsutism.5
The following clinical presentations, and biochemical 
profile, were used to identify subjects with suspected 
PCOS: 1) menstrual irregularities (MI) such as oligomen-
orrhea, anovulation (defined as menstrual cycles .35 days 
and/or with #8 cycles/year), and/or the presence of chronic 
amenorrhea,1 and 2) clinical hyperandrogenism (HA) 
(ie, hirsutism, alopecia, acne, and/or a modified Ferriman–
Gallwey [mFG] score $17) and/or subclinical features, with 
biochemical HA that is evident by an increase in serum-
free testosterone in adult females above the normal level 
of .0.663 nmol/L, and mFG score defined as the extent 
of hair growth in a male pattern on 19 different body parts 
of a woman, measured on a severity scale of four.8 The 
NIH criteria were selected as they are used extensively for 
screening and in epidemiological studies, due to the lack of 
an ultrasound device in the university clinic, and because 
the majority of students who were single refused to go 
through clinical gynecological examination. The inclusion 
criteria were as follows: age 18–30 years, menarche from 
10 to 15 years, no history of anatomical deformity, no use 
of tablets or hair-removal methods, normal prolactin and 
thyroid-stimulating hormone (TSH) levels, and a history 
of MI, such as oligomenorrhea and amenorrhea. Diagnosis 
of idiopathic hirsutism (IH) is one of the exclusion criteria 
used in this study, in which ovulatory dysfunction, HA, 
and other defined androgen excess disorders are ruled 
out. In the current study, subjects with a normal level of 
testosterone who used hair removal methods such as laser 
and/or dermatological treatment to improve hirsutism were 
considered to have IH.9
study protocols
anthropometric measurements, questionnaire, and 
Ferriman–gallwey assessment
All participants went through anthropometric examina-
tions, including weight and height; body mass index (BMI) 
was calculated by dividing the weight (kg) by the square 
meters of height (m2), and obesity was defined if BMI 
was $30 kg/m2. All participants filled out a questionnaire 
providing details of their general demographic information 
(such as age and nationality) and medical history, including 
specific questions regarding known diagnosis of PCOS, 
diabetes, hypertension, cardiovascular disease, and family 
history of these conditions. The questionnaire also requested 
answers about menstrual history and lifestyle, including 
pharmaceutical history (Figure S1). The mFG was self-scored 
after explanation and demonstration of full details to all 
participants. A score .17 was considered HA as previously 
published among women of the same ethnic background in 
Arab Gulf States.10
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Biochemical assay
Overnight fasting blood samples were drawn, followed by 
centrifugation, and serum was collected into aliquots and 
stored at -80°C for further hormonal assay. Blood glucose 
was measured by an enzymatic colorimetric assay in the 
clinical chemistry laboratory at QU. Hormonal tests, includ-
ing TSH, prolactin, insulin, testosterone, dehydroepiandros-
terone sulfate (DHEAS), and sex hormone-binding globulin 
(SHBG), were conducted in the Chemistry Laboratory at 
Hamad Medical Corporation, Doha, Qatar. The principle 
of the assay used was chemiluminescent microparticle 
immunoassay (CMIA) for the quantitative determination 
of the following hormones: testosterone, DHEAS, insu-
lin, TSH, prolactin, and SHBG in human serum. The free 
testosterone was calculated from total testosterone levels, 
albumin, and SHBG using a specified formula that has been 
used as a diagnostic tool for HA.11 Free androgen index 
(FAI) was also calculated as the total testosterone level 
in nmolL divided by the SHBG level in nmol/L and then 
multiplied by 100. FAI .4.5 was considered as a marker 
of biochemical HA.12
The interassay coefficient of variations % of the measured 
hormones was SHBG #10%, TSH #10%, DHEAS #10%, 
testosterone #10%, prolactin #6%, and insulin #10%. The 
cutoff values of the Endocrine Laboratory at Hamad Medical 
Corporation were used in this study (Table S1). TSH and 
prolactin were measured to exclude cases of MI caused by 
hyperprolactinemia and thyroid disturbances.
Power calculation
In the year 2011, there were 6,000 QU students, of 
whom ~50% were Qatari, and nearly 50% of the Qatari 
students were females (1,500). 
Previous publications indicate that prevalence (p) of 
PCOS is 0.05–0.10 setting of the confidence interval (Z) is 
0.55, and precision (d) is 0.2, so we needed to study 118 
out of 2,000 subjects to be able to reject the null hypothesis 
with probability (power) of 0.8. The type I error probability 
associated with this test of null hypothesis is 0.05. This 
percentage represents a good portion as a sample size of 
young females in Qatar, which is a country with a small 
population.
statistical analysis
Data were explored for outliers, skewness, and normality and 
transformed when necessary if normality assumption was 
violated. Continuous data are expressed as mean ± SD for 
normally distributed variables, median and interquartile range 
(25%–75%) for nondistributed continuous data, and number 
and (percentage) for categorical data. Two Student’s t-tests 
and nonparametric Mann–Whitney test evaluated the differ-
ences between continuous variables, and two-independent 
samples t-tests were used accordingly for analysis. Chi-
square test evaluated differences between categorical vari-
ables. The two-tailed P#0.05 was considered as the cutoff 
value for significance. All statistical analyses were carried out 
using IBM SPSS Statistics 22.0 for Mac XP (IBM Corpora-
tion, Armonk, NY, USA) and GraphPad prism (Version 6, 
for Mac; GraphPad Software, La Jolla, CA, USA).
Results
The demographic, clinical and biochemical, 
and hormonal characteristics of the 
study subjects based on their clinical 
presentations of PcOs
Table 1 shows the comparison of the median and the inter-
quartile values of the different variables for all study subjects, 
and further, between the control (non-PCOS) and the PCOS 
groups, among the study subjects. All the participants were 
within the age group range of 18–30 years, with a median 
age of 21 years. The participants’ median and interquartile 
range of BMI was 22.95 (19.95–25.81) kg/m2, and 11.6% 
of the participants were obese. No significant difference in 
age, BMI, age at menarche, and blood glucose was detected 
between non-PCOS and PCOS groups as listed in Table 1. 
The PCOS group exhibited significantly higher frequencies of 
MI and hirsutism than the non-PCOS group, with a P-value of 
,0.05, as listed in Table 1. Clinical hirsutism assessed by the 
“mFG score” was found in 38 cases of the study, of whom 16 
had IH. Among the hormones assayed, the total testosterone, 
DHEAS, free testosterone, and FAI are significantly higher 
in PCOS subjects than in non-PCOS subjects (P#0.0001), 
as listed in Table 1. In contrast, no significant difference in 
the median concentrations of SHBG, insulin, prolactin, and 
TSH was detected between the two groups.
The frequency of PcOs among the study 
subjects and the risk factors for PcOs
Of the 120 study subjects, 22 students met the NIH criteria 
for PCOS diagnosis, resulting in a frequency of 18.33%, 
and their main diagnostic criteria are listed in Table S2. All 
PCOS cases had oligo–anovulation and clinical/biochemical 
HA (100.0% had hirsutism with a score of $17.0, 63.6% had 
acne, and 83.4% had abnormally elevated FAI, but none had 
abnormal free testosterone level). Table 2 shows the relative 
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risk factors between the PCOS and the control subjects. Of 
interest, PCOS subjects have significantly higher frequencies 
of family history of PCOS, acne, and obesity than the control 
subjects with P-values 0.003, 0.023, and 0.0005, respectively. 
Although PCOS subjects exhibited higher frequency of fam-
ily history of diabetes and hyperinsulinemia, the difference 
was not significant when compared with the non-PCOS 
subjects (P.0.05), as shown in Table 2.
The biochemical and hormonal features 
of subjects presenting with MI
This study highlights the median and interquartile values 
of the different hormone concentrations and FAI in all 
the study subjects with MI and their P-values, as listed 
in Table 3. Of interest, MI subjects with PCOS have 
significantly higher median values of free as well as total 
testosterone, DHEAS, and FAI than MI subjects with non-
PCOS. No significant difference was found between the 
two groups for SHBG, TSH, prolactin, and insulin, with 
P-value .0.05.
Discussion
This study investigated the hormonal and phenotype profile 
and the frequency of PCOS among young female students 
in the age group of 18–30 years. The study highlighted 
important data about the frequency and the hormonal and 
phenotype profile in PCOS subjects as well as in subjects 
presenting with MI, among this young female study popu-
lation. Such findings will be discussed in the following 
paragraphs.
The frequency of PCOS in this study was 18.33% 
according to the NIH criteria. PCOS prevalence depends 
on the recruitment process of the study population and the 
criteria used for its diagnosis and definition. Two studies 
on PCOS in Iran reported PCOS prevalence rates of 11.7 
and 7% based on the NIH criteria, respectively.13,14 The 
frequency of PCOS by the NIH standards in a community-
based study in Sri Lanka was 6.3% in women aged between 
15 and 39 years.15 A recent assessment of the frequency of 
PCOS in North India was 3.7% in women aged between 
18 and 25 years.16 The frequency of PCOS in Caucasian 
women from Madrid, Spain, was 6.5%.17 A recent study 
among Palestinian subjects aged 18–24 years reported a 
PCOS prevalence of 7.3%.18 The discrepancy between the 
previous studies regarding the prevalence of PCOS and 
the data of this study could be attributed to the recruitment 
process of the study subjects, small sample size, age differ-
ence, and/or ethnic background. For example, the age group 
Table 1 clinical and biochemical characteristics of all study subjects, non-PcOs and PcOs
Variables All study subjects Non-PCOS (n=98, 81.67%) PCOS (n=22, 18.33%) P-value
age, median (IQr), years 21.00 (19.00–22.50) 22.0 (19.00–22.50) 21.00 (20.00–22.00) 0.921
BMI, median (IQr), kg/m2 22.95 (19.95–25.81) 23.37 (19.95–24.96) 23.93 (19.90–28.48) 0.155
age of menarche, median (IQr), years 12.00 (11.00–13.00) 12.00 (11.00–13.00) 12.00 (12.0–13.0) 0.915
Hirsutism, n (%) (mFg score .17) 38 (31.7) 16 (16.3) 22.0 (100) 0.028
Menstrual irregularities, n (%) 37 (30.8) 15 (15.3) 22 (100) 0.017
acne, n (%) 37 (30.8) 23 (23.5) 14 (63.6) 0.023
glucose, median (IQr), mg/dl 88.00 (81.50–97.50) 87.00 (82.00–96.00) 90.50 (80.00–101.50) 0.701
Total testosterone, median (IQr), nmol/l 1.39 (0.77–2.28) 1.30 (0.60–1.79) 2.70 (2.04–3.45) ,0.0001
DHeas, median (IQr), µmol/l 8.13 (6.04–10.11) 7.40 (5.54–9.56) 10.1 (8.06–13.64) ,0.0001
sHBg, median (IQr), nmol/l 51.00 (45.00–62.00) 51.00 (37.50–67.00) 45.00 (28.00–62.00) 0.0697
Free testosterone, median (IQr), nmol/l 0.023 (0.008–0.036) 0.017 (0.013–0.020) 0.043 (0.037–0.049) ,0.0001
Insulin, median (IQr), mIU/l 12.00 (6.00–25.00) 12.00 (6.00–23.50) 14.00 (6.00–31.00) 0.259
Prolactin, median (IQr), mIU/l 320.5 (225.50–457.50) 312.00 (211.0–471.0) 361.00 (266.0–401.0) 0.195
TsH, median (IQr), mIU/l 1.47 (1.09–1.98) 1.47 (1.14–1.95) 1.44 (1.02–2.40) 0.876
FaI, median (IQr) 2.80 (1.17–5.17) 1.86 (1.12–3.76) 5.75 (3.14–10.93) ,0.0001
Notes: Descriptive characteristics obtained by Wilcoxon/Kruskal–Wallis tests with nonparametric comparison for each pair using Wilcoxon method. categorized data were 
analyzed by chi-square test. Two-tailed P-value ,0.05 is significant. Free testosterone was calculated by subtracting the testosterone bound to SHBG and albumin.
Abbreviations: BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; IQR, interquartile range; mFG, modified Ferriman–Gallwey; 
PcOs, polycystic ovary syndrome; sHBg, sex hormone-binding globulin; TsH, thyroid-stimulating hormone.
Table 2 relationship between possible risk factors and PcOs in 
the study subjects and after adjustment for the confounding factors
Risk factors Non-PCOS PCOS P-value
FH of PcOs, n (%) 8 (8.2) 9 (40.9) 0.003
FH of diabetes, n (%) 55 (56.1) 21 (95.5) 0.156
acne, n (%) 23 (23.5) 14 (63.6) 0.023
Hyperinsulinemia 
(.23.0 mIU/l), n (%)
26 (26.5) 9 (40.9) 0.343
Obesity, n (%) 5 (5.1) 9 (40.9) 0.0005
Notes: Data were analyzed by chi-square test for comparison between non-PcOs 
and PcOs groups, with their corresponding P-values. Odds ratio and 95% cI were 
analyzed by logistic regression with the adjustments of these factors with their 
P-value. Two-tailed P-value #0.05 is significant.
Abbreviations: FH, family history; PcOs, polycystic ovary syndrome.
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of this study sample was narrow, including women aged 
18–30 years, while some other studies included women aged 
18–45 years to limit the phenomenon of irregular menstrual 
cycles in early age and premenopausal age. The recruitment 
of the study subjects was an unselected group of students. 
Due to the nature of the study, this could have encouraged 
some students experiencing PCOS-like symptoms to come 
forward for this study, while others without PCOS were 
not involved in PCOS screening, which could have had an 
impact on the results of this present study. On the contrary, 
previous studies have often used hospital settings such as 
blood donation centers19 and in vitro fertilization (IVF) 
clinic patients,20 who might be considered as biased samples. 
Females who donate blood are generally healthy, which 
could account for the low frequency of PCOS in those study 
groups. However, on the contrary, subjects recruited from 
IVF clinic patients desiring conception may have gyne-
cological problems such as PCOS-like conditions, which 
may explain the high frequency of PCOS in those study 
groups. Similar concerns have been voiced by the United 
Arab Emirates (UAE) fertility clinics, that the frequency 
of PCOS in the Gulf region and South Asia appears to be 
much higher, though no exact figures are available.21 Also, 
the difference in the definition of HA may also account for 
the difference in the frequency of PCOS among different 
studies worldwide. Knochenhauer et al22 defined HA by 
Ferriman–Gallwey score only. In this study, HA was defined 
either clinically by evidence of hirsutism (mFG score $17), 
with acne, or biochemically by increased free testosterone 
level above the cutoff value .0.663 nmol/L and FAI.23 
Clinical hirsutism was found in 31.7% of all study subjects 
and 100.0% of PCOS subjects. In fact, we did not consider 
females with only acne to be hyperandrogenic because 
acne may be due to Propionibacterium. Different studies in 
Srilanka,15 Spain,17 and Palestine18 had utilized a different 
range for Ferriman–Gallwey score (hirsutism defined by a 
score of $8). Meanwhile, we followed the model used by 
the neighboring countries of similar ethnic background, such 
as Saudi Arabia, Bahrain, and UAE, with a score of $17. 
We found in this study that among the PCOS group, 100% 
had clinical hirsutism. The frequency of facial hirsutism 
without PCOS remains unclear in this region of the world, 
although PCOS continues to be one of the most common 
causes of hirsitism. Previous studies in Arab Gulf countries 
showed that PCOS is the leading cause of hirsutism among 
women and reached 82% and 91% in Saudi Arabia and 
UAE based studies, respectively.10,11 IH can not be solely 
excluded from the PCOS diagnosis since many women may 
report that they have regular periods despite oligoovulation. 
This finding further warrants studying ethnic diversity in 
androgenic manifestation.
In this study, of the 22 cases of PCOS, four (3.31%) cases 
had been previously diagnosed with infertility problems 
and 18 new cases were defined, implying that ~82% of the 
young women were unaware of their health condition. The 
same idea was echoed in a cohort study in Australia, which 
found that 68%–69% of the diagnosed females with PCOS 
were unaware of their status.25 Hence, the study also draws 
attention to the issues of many women with PCOS in the 
community who remain undiagnosed.
This study showed that having a family history of PCOS 
is a significant risk factor for developing PCOS (P=0.0001). 
This idea is reflected in the literature claiming PCOS to be 
familial,26 and various factors may be differentially inherited. 
Ideally, circulating free testosterone is used as a marker for 
the detection of PCOS,23 but another study has shown that 
DHEAS also plays a significant role in causing HA and 
could be used as a biomarker for HA.27 This study revealed 
that high level of DHEAS is a significant finding in PCOS, 
which is consistent with a previous study.28
Table 3 Biochemical features of MI subjects
Laboratory test All MI MI (non-PCOS) MI with PCOS P-value
Free testosterone (nmol/l) 0.032 (0.021–0.042) 0.015 (0.005–0.025) 0.039 (0.031–0.047) 0.0002
T testosterone (nmol/l) 2.04 (0.92–2.71) 0.91 (0.70–1.29) 2.61 (2.03–3.06) 0.0001
DHeas (µmol/l) 8.67 (6.63–10.91) 6.96 (5.58–8.13) 9.84 (8.22–12.11) 0.0026
sHBg (nmol/l) 55.0 (29.5–69.00) 67.00 (47.00–72.00) 50.00 (26.50–62.00) 0.0580
FaI 2.79 (1.17–5.15) 2.67 (1.14–4.95) 3.58 (1.36–7.65) ,0.0001
TsH (mIU/l) 1.28 (1.07–2.19) 1.24 (0.99–1.47) 1.36 (1.08–2.49) 0.516
Prolactin (mIU/l) 331.00 (273.00–395.00) 324.00 (283.00–372.00) 360.50 (269–395.76) 0.465
Insulin (mIU/l) 14.00 (5.50–35.50) 12.00 (5.00–34.00) 14.50 (6.00–37.00) 0.467
Notes: Data are presented by median and IQr values (25%–75%). Data were calculated by nonparametric comparison for each pair using Wilcoxon method. Two-tailed 
P-value ,0.05 is significant.
Abbreviations: DHeas, dehydroepiandrosterone sulfate; FaI, free androgen index; IQr, interquartile range; MI, menstrual irregularities; PcOs, polycystic ovary syndrome; 
sHBg, sex hormone-binding globulin; T, total; TsH, thyroid-stimulating hormone.
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In females, the ovaries and adrenal glands are responsible 
for the production of androgens. According to a study by 
Azziz,1 total testosterone .4.8 nmol/L is considered a sign 
of an androgen-secreting tumor, but none of our samples had 
a level .4.8 nmol/L. Also, another study showed that tumors 
with total testosterone slightly .2 nmol/L were extremely rare 
(18 out of 400 cases). Actually, as in most previous studies, we 
were not able to control the collection of blood samples at the 
time of the menstrual periods of participants due to irregular 
periods in these PCOS subjects. Knochenhauer et al22 and 
Asuncion et al17 have discussed that none of these factors have 
a significant effect on the circulating levels of androgens.
In our population sample, only four females had 
type 1 diabetes, detected among the control subjects, and 
none had type 2 diabetes. However, elevated insulin levels 
were prevalent (41%) in the PCOS group, but no cases were 
diagnosed with type 2 diabetes. A study conducted in Boston, 
MA, USA, reported that 7.5% of PCOS women had type 2 
diabetes.29 Possible causes of not detecting any diabetes in 
the PCOS group could be due to no data on the oral glucose 
tolerance test (OGTT) to diagnose hyperglycemia, and the 
young age of the study participants. Although hyperinsuline-
mia is linked to PCOS in previous studies,2,4 the current data 
did not support such correlations. Such conflicting results 
could be due to the difference in the sample size, the study 
populations, and the heterogeneity of PCOS syndrome.
This study found that clinical risk factors that are sig-
nificantly associated with PCOS are family history of PCOS 
and acne. A previous study by Azziz and Kashar-Miller30 
noted that “35% of mothers and 40% of sisters of patients 
with PCOS will be affected by PCOS themselves”, which 
is consistent with the results of this study. Acne was pres-
ent in 63.6% of PCOS subjects in this study. This is in line 
with previous studies showing that PCOS subjects had acne 
at a rate of 50%–80% in Turkey31 and Palestine.18 Among 
hormones, we found that DHEAS, testosterone, and SHBG 
are significantly associated with PCOS. A previous study 
by Asuncion et al17 in Spain demonstrated that DHEAS, 
testosterone, FAI, and SHBG are significant factors associ-
ated with PCOS. In this study, there were significantly higher 
testosterone (free and total), DHEAS, and FAI concentrations 
in PCOS subjects who had MI, which met the definition of 
PCOS, than in non-PCOS subjects (Table 3). The current 
data suggest that PCOS subjects with MI have higher levels 
of androgens than non-PCOS subjects, consistent with the 
definition of PCOS elsewhere.1,30
To the best of our knowledge, the association between 
this phenotype profile and the frequency of PCOS is the first 
of its kind to be gauged in this country. The current findings 
of phenotype profile and the frequency of PCOS of 18.33% 
cannot be used to extrapolate to the whole population of 
Qatar due to the low sample size, age distribution, and the 
selection confined to university students only. The strength of 
this study is that it is one of the first PCOS studies investigat-
ing the frequency and phenotypic profile of young females 
in Qatar. Using the international criteria by the NIH in this 
study, applicable data were drawn from the PCOS risk fac-
tors, frequency, and hormonal profile, so that further studies 
can be built on this data.
Conclusion
The frequency of PCOS among females aged 18–30 years in 
Qatar is found to be 18.33% using the NIH criteria. This study 
had several limitations; one of the most important was the 
limited sample size. Limited resources, such as ultrasound, 
at Qatar University clinic were an obstacle to evaluating the 
study subjects by another criterion, such as the Rotterdam cri-
teria. mFG scoring was done by the participants themselves 
after demonstrations and instructions, which may have been 
influenced by social desirability bias.
Further studies should be conducted on a larger sample 
size. Longitudinal studies must be carried out to determine 
the long-term effects of PCOS on female health in Qatar.
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Supplementary materials
Questionnaire
Age:
Gender:
Weight (kg):
Height (m):
Patient history
• Diabetes mellitus
• Hypertension
• Dyslipidemia
• Anorexia or bulimia
• Hypothyroidism
• Use of oral contraceptives
• Anxiety or stress disorders
• Anemia
• Age of menarche
• Medical disorder
• Obesity: what age
• Infertility
• Family history of PCOS, obesity, and DM
• Drug use/type
Oligomenorrhea
• Variable or long menstrual cycles
• ,9 menses annually
• Irregular menses with weight gain
Pregnancy
• Previously pregnant
• Previously attempted
• Previously attempted without success for $1 year
Nipple discharge exclusive of pregnancy or breastfeeding
Coarse hair growth
• At 1 or more sites
• At 2 or more sites
• At 3 or more sites
• Troubled by hair growth
• Treatment for hair growth
• Increased growth with weight gain
Had acne as an adult
• Medical treatment for acne
Family history: please tick if any
�  Diabetes  �  PCOS
�  Acne �  Hirsutism
�  Eating disorders �  Obesity
�  Hypertension �  Dyslipidemia
�  Hyperparathyroidism �  Kidney diseases
�  Liver diseases �  Anemia
�  Blood clotting disorders �  Autoimmune disorders
�  Cancer �  Urinary tract infections
Figure S1 (Continued)
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Please tick if you have one of the following complaints:
Complaint Please tick if any = yes
Mood disorders
Anxiety
Bulimia
Nausea
Vomiting
Anorexia
Weight changes
Constipation
Diarrhea
Dermatological problem
Life style changes:
Gain weight
Food: type and quantity
Appetite
Mood changes
Relationship with others
Figure S1 Patient questionnaire.
Abbreviations: DM, diabetes mellitus; PcOs, polycystic ovary syndrome.
Table S1 cutoff values for hormones used by Hamad Medical corporation, Qatar
Hormone Cutoff value
Prolactin 109–557 mIU/l
Testosterone 0.69–2.78 nmol/l
DHeas 3.6–11.10 µmol/l
sHBg 20–100 nmol/l
Insulin 1.9–23 mIU/l
glucose 105 mg/dl
TsH 0.45–4.5 mIU/l
Abbreviations: DHeas, dehydroepiandrosterone sulfate; sHBg, sex hormone-binding globulin; TsH, thyroid-stimulating hormone.
Table S2 Participants who met the individual nIH diagnostic criteria for PcOs (n=22, 18.33%)
Criteria n (%)
clinical or biochemical hyperandrogenism, n (%) 22 (100.0)
Hirsutism 22 (100.0)
clinical hyperandrogenism (%) 22 (100)
acne 14 (63.30)
Increased free testosterone 0.0 (0.0)
Increased FaI 19 (86.36)
Biochemical hyperandrogenism (%) 19 (86.36)
Oligoovulation 22 (100.0)
chronic oligomenorrhea and/or amenorrhea 22 (100.0)
Menstrual irregularity + clinical hyperandrogenism 22 (100)
Menstrual irregularity + biochemical hyperandrogenism 19 (86.36)
exclusion of secondary causes 22 (100)
Note: Values are raw numbers (percentage).
Abbreviations: FaI, free androgen index; nIH, Us national Institutes of Health; PcOs, polycystic ovary syndrome.
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